T23 Biopharmaceuticals logo

T23 Biopharmaceuticals

T23 Biopharmaceuticals, is a biotech company, focused on the development of immunotherapies for the treatment of patients with cancer & autoimmune disease.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://t23bio.com
Founded2014
Disease Focus
Development StagePreclinical
STOCK CODENon Listed
Address
6605 Nancy Ridge Drive, Ste 207, CA 92121
San Diego
United States
Email
Contact Number
+1 858-724-0581

T23 Biopharmaceuticals, is a biotech company, focused on the development of immunotherapies for the treatment of patients with cancer & autoimmune disease.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Jun 2014, The Scripps Research Institute liscence T23 Biotherapeutics an exclusive, worldwide rights to develop, manufacture and commercialize Scripps CD22 sialic acid binding Ig-like lectin (SIGLEC) onco-immunological platform.